• Successful completion of technical proof of concept with Provider Network Solutions (PNS)
• Accelerated progression to Phase 2 of MOU for commercial pilot with PNS
• Finalised development of PACS-agnostic 3Dicom Gateway

The March 2025 quarter marked a pivotal period for Singular Health Group Limited (ASX: SHG) as it achieved several key strategic and technical milestones. The Company completed ahead of schedule Phase 1 of the Memorandum of Understanding (MoU) with US-based Provider Network Solutions LLC (PNS), validating a technical proof of concept for the 3Dicom platform. This success led to the advancement to Phase 2, which centres on defining the commercial and technical framework for a paid pilot project. Concurrently, steps are underway to establish a partnership between Singular Health and PNS to commercialise the 3Dicom solution within the MSO ecosystem in the USA. The Company also finalised the development of the 3Dicom Gateway, enabling PACS-agnostic retrieval of medical imaging data and seamless real-time access through the web-based 3Dicom MD viewer. During the quarter, Singular Health secured over $965k in funding, including a $500k cornerstone investment from PNS and $465k via exercised options, significantly boosting cash at bank and reinforcing readiness for the upcoming U.S. pilot program. The Company maintained strong engagement with shareholders and the broader investment community, conducting a series of investor meetings that attracted interest from institutional investors.

The Company expects to execute and deploy the planned pilot program with PNS and further enhance the 3Dicom platform's usability and compliance in the June 2025 quarter.

Singular Health is well-positioned financially and commercially to build on its strong momentum, with a robust technical foundation, growing strategic partnerships, solid financial position, and low operating expenditure providing a clear pathway to commercialisation.